FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 346:2022-2023 June 27, 2002 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Walmsley, S. PubMed Citation

The field of antiretroviral therapy has witnessed remarkable progress during the past 15 years. There are now 16 approved therapeutic agents for infection with the human immunodeficiency virus (HIV), a pathogen that once caused nearly uniformly fatal illness. These agents target two essential enzymes of the virus, the reverse transcriptase and the protease (see Figure). The era of potent antiretroviral therapy, also termed highly active antiretroviral therapy, began in 1996 and has been marked by dramatic declines in morbidity and mortality due to HIV disease in the developed world. These advances have not been without their cost in terms . . . [Full Text of this Article]

This article has been cited by other articles:

• Busse, K. H. S., Penzak, S. R. (2007). Darunavir: A second-generation protease inhibitor. Am J Health Syst Pharm 64: 1593-1602 [Abstract] [Full Text]  
• Stebbing, J, Bower, M, Holmes, P, Gazzard, B, Nelson, M (2006). A single centre cohort experience with a new once daily antiretroviral drug.. Postgrad. Med. J. 82: 343-346 [Abstract] [Full Text]  
• Stebbing, J, Sawleshwarkar, S, Michailidis, C, Jones, R, Bower, M, Mandalia, S, Nelson, M, Gazzard, B (2005). Assessment of the efficacy of total lymphocyte counts as predictors of AIDS defining infections in HIV-1 infected people. Postgrad. Med. J. 81: 586-588 [Abstract] [Full Text]  
• Latham, V., Stebbing, J., Mandalia, S., Michailidis, C., Davies, E., Bower, M., Gazzard, B., Nelson, M. (2005). Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J Antimicrob Chemother 56: 186-189 [Abstract] [Full Text]  
• Orkin, C., Stebbing, J., Nelson, M., Bower, M., Johnson, M., Mandalia, S., Jones, R., Moyle, G., Fisher, M., Gazzard, B. (2005). A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother 55: 246-251 [Abstract] [Full Text]  
• Salomon, J. A, Weinstein, M. C, Goldie, S. J (2004). Taking account of future technology in cost effectiveness analysis. BMJ 329: 733-736 [Full Text]  
• Waters, L., Stebbing, J., Jones, R., Michailidis, C., Sawleshwarkar, S., Mandalia, S., Bower, M., Nelson, M., Gazzard, B. (2004). A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. J Antimicrob Chemother 54: 503-507 [Abstract] [Full Text]  
• Stebbing, J., Nelson, M., Orkin, C., Mandalia, S., Bower, M., Pozniak, A., Gazzard, B. (2004). A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). J Antimicrob Chemother 53: 501-505 [Abstract] [Full Text]